SomaLogic announced today the establishment of a framework "Partnership for Personalized Health" with the Leeds Centre for Personalised Medicine and Health (CPMH) Read More »

As part of its continued support of the American Heart Association's Go Red For Women movement, CVS Health extended its commitment to women's health by offering no cost Read More »

McKesson Medical-Surgical and Sysmex America today announced plans for McKesson to be the exclusive distribution partner for Sysmex's new XW-100 automated hematology analyzer, the first Clinical Laboratory Improvement Amendments (CLIA)-waived, complete blood count (CBC) diagnostic instrument. Read More »

Upsher-Smith Laboratories, LLC (Upsher-Smith) announced that it has received U.S. Food and Drug Administration (FDA) approval of its abbreviated new drug application (ANDA) for Bumetanide Tablets, USP, 0.5 mg, 1 mg, and 2 mg. Read More »

Proprietary technology enables and helps guide specialty pharmacist interactions with patients prescribed oral oncology medications Read More »

Mallinckrodt plc confirmed enrollment of the first patient in the company's Phase 4, multi-center, randomized, double-blind, placebo-controlled pilot study to further assess the efficacy of H.P. Read More »

Label Variation to Include Overall Survival Data From Phase 3 ENDEAVOR Trial Read More »

The National Institutes of Health is teaming with government, biopharmaceutical, life science and non-profit organizations to overcome obstacles and increase success for advancing promising treatments for Parkinson’s disease (PD). Read More »

​Officially approved for leukemia treatment by the FDA just one month ago, Pfizer Inc.’s BESPONSA has gained a primary distributor to provide the drug to pharmacies across the U.S.  Read More »

ScriptSave WellRx earned honors at the National Association of Chain Drug Stores (NACDS) Total Store Expo (TSE) this year in San Diego, California, for its Personalized Wellness, designated the front end services product showcase winner. Read More »

A generic formulation of AstraZeneca’s Nexium medication that delivers time-released doses of the drug to aid acid-reflux sufferers has received FDA approval and should soon be available for purchase. Read More »

Taxes are lower, ISIS is on the run, and the regulatory agencies are in a ceasefire with the US economy. Read More »

The Rite Aid Foundation recently announced the rollout of its KidCents Safe Medication Disposal Program, which will focus on reducing drug accessibility, medication misuse and accidental poisoning of children and adolescents. Read More »

The makers of a new, opioid-free inhalable pain reliever have launched a campaign to market the drug to more than 9,000 women’s healthcare providers across the U.S. this fall. Read More »

Novartis recently announced that the U.S. Food and Drug Administration (FDA) approved Kymriah suspension for intravenous infusion for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Read More »

Merck and researchers from the Clinical Trial Service Unit at the University of Oxford recently announced positive results for the REVEAL Study. Read More »

Coherus BioSciences Inc. of Redwood City, California recently announced initial results from several current clinical pharmacokinetic bioequivalence (PK/BE) studies comparing two products, both developed for the purpose of addressing certain chronic arthritic and skin conditions. Read More »

Endo International plc of Dublin, Ireland recently launched shipping operations for its generic Sabril (vigabatrin for oral solution USP, 500 mg) product via Par Pharmaceutical, following final approval of its Abbreviated New Drug Application (ANDA). Read More »

Orfadin, a drug used to treat a condition causing kidney and liver damage, has now received the FDA’s go-ahead for once-a-day use, cutting its dosing frequency in half. Read More »

Accorda Therapeutics Inc. recently announced that the U.S. Food and Drug Administration (FDA) provided a Refusal to File (RTF) letter regarding the company’s New Drug Application (NDA) for Inbrija, an investigational treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen. Read More »